Management of chronic hepatitis C in 2012 in Belgium;Prise en charge de l'heṕatite C chronique en 2012 en Belgique

Revue Medicale de Bruxelles

Volumn 33, Issue 4, 2012, Pages 223-227

  Moreno, C ^a   Deltenre, P ^b,c  

^a ERASME HOSPITAL   (Belgium)

^b Hospital de Jolimont   (Belgium)

^c LILLE UNIVERSITY HOSPITAL   (France)

Author keywords

Chronic hepatitis C; Liver fibrosis; Sustained virological response; Triple therapy

Indexed keywords

BOCEPREVIR; PEGINTERFERON; RIBAVIRIN; TELAPREVIR; VIRUS RNA;

ARTICLE; BELGIUM; COMBINATION CHEMOTHERAPY; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; LIVER FIBROSIS; TREATMENT RESPONSE;

ANTIVIRAL AGENTS; BELGIUM; DRUG COMBINATIONS; DRUG INTERACTIONS; HEPATITIS C, CHRONIC; HUMANS; MODELS, BIOLOGICAL; OLIGOPEPTIDES; PROLINE;

EID: 84867556026     PISSN: 00353639     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. Beutels M, Van Damme P, Aelvoet W et al. : Prevalence of hepatitis A, B and C in the Flemish population. Eur J Epidemiol 1997; 13 : 275-80 (Pubitemid 27306072)
2. Marcellin P, Pequignot F, Delarocque-Astagneau E et al. : Mortality related to chronic hepatitis B and chronic hepatitis C in France : evidence for the role of HIV coinfection and alcohol consumption. J Hepatol 2008; 48 : 200-7
3. Deuffic S, Buffat L, Poynard T et al. : Modeling the hepatitis C virus epidemic in France. Hepatology 1999; 29 : 1596-601 (Pubitemid 29211066)
4. Deuffic-Burban S, Deltenre P, Louvet A et al. : Impact of viral eradication on mortality related to hepatitis C : a modeling approach in France. J Hepatol 2008; 49 : 175-83
5. Alberti A, Chemello L, Benvegnu L : Natural history of hepatitis C. J Hepatol 1999; 31 (Suppl 1) : 17-24 (Pubitemid 30002686)
6. Friedman SL : Hepatic stellate cells : protean, multifunctional, and enigmatic cells of the liver. Physiol Rev 2008; 88 : 125-72
7. Craxi A : EASL Clinical Practice Guidelines : Management of hepatitis C virus infection. J Hepatol 2011; 55 : 245-64
8. Ryder SD : Outcome of hepatitis C infection : bleak or benign ? J Hepatol 2007; 47 : 4-6
9. Jacobson IM, Davis GL, El-Serag H et al. : Prevalence and challenges of liver diseases in patients with chronic hepatitis C virus infection. Clin Gastroenterol Hepatol 2010; 8 : 924-33
10. Fattovich G, Giustina G, Degos F et al. : Morbidity and mortality in compensated cirrhosis type C : a retrospective follow-up study of 384 patients. Gastroenterology 1997; 112 : 463-72 (Pubitemid 27078833)
11. Degos F, Christidis C, Ganne-Carrie N et al. : Hepatitis C virus related cirrhosis : time to occurrence of hepatocellular carcinoma and death. Gut 2000; 47 : 131-6 (Pubitemid 30430422)
12. Sangiovanni A, Prati GM, Fasani P et al. : The natural history of compensated cirrhosis due to hepatitis C virus : A 17-year cohort study of 214 patients. Hepatology 2006; 43 : 1303-10 (Pubitemid 43980109)
13. El-Serag HB, Mason AC, Key C : Trends in survival of patients with hepatocellular carcinoma between 1977 and 1996 in the United States. Hepatology 2001; 33 : 62-5 (Pubitemid 32016888)
14. D'Amico G, Garcia-Tsao G, Pagliaro L : Natural history and prognostic indicators of survival in cirrhosis : a systematic review of 118 studies. J Hepatol 2006; 44 : 217-31 (Pubitemid 41772537)
15. Trinchet JC : [Natural history of HCV infection]. Gastroenterol Clin Biol 2002 ; 26 (Spec 2) : B144-53
16. Deltenre P : Virological tools for optimal management of chronic hepatitis C. Acta Gastroenterol Belg 2009; 72 : 421-4
17. Alberti A : Impact of a sustained virological response on the long-term outcome of hepatitis C. Liver Int 2011; 31 (Suppl 1) : 18-22
18. Hezode C, Forestier N, Dusheiko G et al. : Telaprevir and peginterferon with or without ribavirin for chronic HCV infection. N Engl J Med 2009; 360 : 1839-50
19. McHutchison JG, Everson GT, Gordon SC et al. : Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection. N Engl J Med 2009; 360 : 1827-38
20. Kwo PY, Lawitz EJ, McCone J et al. : Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT-1) : an open-label, randomised, multicentre phase 2 trial. Lancet 2010; 376 : 705-16
21. Pawlotsky JM : Treatment failure and resistance with direct-acting antiviral drugs against hepatitis C virus. Hepatology 2011; 53 : 1742-51
22. Poordad F, McCone J Jr, Bacon BR et al. : Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med 2011; 364 : 1195-206
23. Jacobson IM, McHutchison JG, Dusheiko G et al. : Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med 2011; 364 : 2405-16
24. Bacon BR, Gordon SC, Lawitz E et al. : Boceprevir for previously treated chronic HCV genotype 1 infection. N Engl J Med 2011; 364 : 1207-17
25. Zeuzem S, Andreone P, Pol S et al. : Telaprevir for retreatment of HCV infection. N Engl J Med 2011; 364 : 2417-28
26. George SL, Bacon BR, Brunt EM et al. : Clinical, virologic, histologic, and biochemical outcomes after successful HCV therapy : a 5-year follow-up of 150 patients. Hepatology 2009; 49 : 729-38
27. Poynard T, McHutchison J, Manns M et al. : Impact of pegylated interferon alfa-2b and ribavirin on liver fibrosis in patients with chronic hepatitis C. Gastroenterology 2002; 122 : 1303-13 (Pubitemid 34465173)